Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131 ·Status: RECRUITING ·Phase: PHASE3

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

NCT06443944 ·Status: AVAILABLE

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

NCT06668493 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Expanded Access for PSV Personalized Oncolytic Viruses

NCT03529539 ·Status: NO_LONGER_AVAILABLE

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743 ·Status: RECRUITING ·Phase: PHASE2

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT05136898 ·Status: COMPLETED ·Phase: PHASE3

Phase I BLASST-3 Trial

NCT04972253 ·Status: WITHDRAWN ·Phase: PHASE1

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

NCT06187506 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

NCT06770582 ·Status: RECRUITING ·Phase: PHASE2

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

NCT07667335 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

NCT06493552 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

NCT06751524 ·Status: AVAILABLE

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

NCT05239624 ·Status: RECRUITING ·Phase: PHASE2

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

NCT05327647 ·Status: RECRUITING ·Phase: PHASE2

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

NCT03287050 ·Status: TERMINATED ·Phase: PHASE2

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

NCT05756569 ·Status: RECRUITING ·Phase: PHASE2

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

NCT04040725 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

NCT07475806 ·Status: RECRUITING ·Phase: PHASE2

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

NCT03801278 ·Status: NO_LONGER_AVAILABLE

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069 ·Status: RECRUITING ·Phase: PHASE1

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931 ·Status: TERMINATED ·Phase: PHASE3

A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

NCT07386847 ·Status: COMPLETED